Investment Thesis
IMMUNIC is a pre-commercial biotech company with virtually no revenue ($22K) and massive operating losses ($33.2M annually), resulting in catastrophic profitability metrics. While the balance sheet is fortress-strong with $186.6M cash and zero debt, the company is burning $17.3M in operating cash annually with no clear near-term path to profitability. The financial fundamentals indicate a speculative pre-revenue stage company dependent entirely on pipeline success and future commercialization.
Strengths
- Fortress balance sheet with $186.6M cash equivalents providing 10+ years of runway at current burn rate
- Zero debt and low liabilities ($38.5M), resulting in clean capital structure
- Excellent liquidity with 4.92x current ratio, eliminating near-term solvency concerns
Risks
- Pre-commercial revenue model with only $22K in revenue and no profitability trajectory visible
- Annual cash burn of $17.3M depleting equity capital despite strong starting position
- Massive negative profitability ratios (operating margin -151068%, net margin -148127%) indicating fundamental business model failure at current stage
- Complete dependence on successful clinical development and commercialization of pipeline products for survival
Key Metrics to Watch
- Revenue growth trajectory and timing of commercial product launches
- Quarterly cash burn rate and updated cash runway estimates
- Clinical trial progress, regulatory approvals, and pipeline advancement milestones
Financial Metrics
Revenue
22.0K
Net Income
-32.6M
EPS (Diluted)
$-1.08
Free Cash Flow
-17.3M
Total Assets
189.7M
Cash
186.6M
Profitability Ratios
Gross Margin
40.9%
Operating Margin
-151,068.2%
Net Margin
-148,127.3%
ROE
-21.5%
ROA
-17.2%
FCF Margin
-78,650.0%
Balance Sheet & Liquidity
Current Ratio
4.92x
Quick Ratio
4.92x
Debt/Equity
0.00x
Debt/Assets
20.3%
Interest Coverage
-2.32x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:32:51.280277 |
Data as of: 2026-03-31 |
Powered by Claude AI